Built on a foundation that leverages over 25 years of North American venture capital experience, the team at Lumira Capital team has an established reputation of building transformational health care and life sciences companies.
We make investments in market-leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses which generate profitable exit opportunities that maximize returns within a reasonable timeframe.
As experienced and trusted business partners, every member of the Lumira team is committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise, established relationships and our operational and leadership experience to help each business achieve its full potential.
At Lumira Capital, our primary investment focus is later stage biopharmaceutical and medical device companies which typically have at minimum preliminary clinical safety and proof of concept data and revenue-generating healthcare businesses poised for high growth. Our geographical focus is businesses located in the United States and Canada.
Source: Lumira Capital
Lumira Capital employs a consistent, proven four-part investment strategy that aims to generate superior returns: First, the company exploits market inefficiencies as a lead investor-of-influence in order to invest at attractive valuations, often by focusing on geographies rich in innovative companies, but where there is limited local venture capital competition. Second, the firm maximizes the exit value of its companies by targeting sectors that are acquisition priorities of multiple acquirers and that have favourable regulatory, market growth and reimbursement dynamics.
Third, the company leverages unique access and insights from its strategic LP, Merck, and often co-invests with the corporate venture arms of leading pharmaceutical and medical technology firms (historically companies with strategic co-investors have produced return multiples 1-2x higher than companies without them).
Finally, Lumira Capital provides investors with accelerated liquidity and lower loss ratios, by investing at value/risk inflection points in a company’s lifecycle, such as after products have already demonstrated proof-of-concept in human clinical studies, and in many cases, early commercial success.
Source: Lumira Capital
Health Care, Biotechnology and Diversified
141 Adelaide Street West, Suite 770,
Toronto, ON, CA. M5H 3L5
Peter van der Velden MBA, Managing General Partner
Gerry Brunk MBA, Managing Director
Brian Underdown PhD, Managing Director